Literature DB >> 41667

Activation of inactive plasma renin by plasma and tissue kallikreins.

F H Derkx, H L Tan-Tjiong, A J Man in 't Veld, M P Schalekamp, M A Schalekamp.   

Abstract

1. Normal human plasma contains a proactivator of inactive renin. The pro-activator is activated at physiological pH in plasma that has been pretreated with acid. This activation in vitro leads to the conversion of inactive renin into the active form with simultaneous generation of kallikrein activity. 2. The endogenous activator of inactive renin has the same pH profile and inhibitor spectrum as plasma kallikrein. 3. Inactive renin can also be activated by exposure of plasma to exogenous trypsin, and in normal plasma the quantities of inactive renin that are activated after acidification and with trypsin are identical. Prekallikrein (Fletcher factor)-deficient plasma, however, has much lower renin activity after acidification than with trypsin. Thus acid activation of inactive renin depends on plasma prekallikrein, whereas the action of trypsin is independent of prekallikrein. 4. Highly purified tissue (pancreatic) kallikrein, in a concentration of less than 2 X 10(-8) mol/l, activates inactive renin that has been isolated from plasma by ion-exchange chromatography. In this respect it is at least 100 times more potent than trypsin. 5. It is therefore possible that plasma and/or tissue (renal) kallikreins are also involved in the activation of inactive renin in vivo.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 41667     DOI: 10.1042/cs0570351

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  18 in total

1.  Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.

Authors:  G J Macphee; C A Howie; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

3.  A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.

Authors:  A D Bainbridge; R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  Haemodynamic profile of captopril treatment in various forms of hypertension.

Authors:  J H de Bruyn; A J Man in't Veld; G J Wenting; F H Derkx; M A Schalekamp
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients.

Authors:  K R Lees; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Localization of kallikrein-like activity along a single nephron in rabbits.

Authors:  K Tomita; H Endou; F Sakai
Journal:  Pflugers Arch       Date:  1981-01       Impact factor: 3.657

7.  Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition.

Authors:  A Overlack; K O Stumpe; M Kühnert; R Kolloch; C Ressel; I Heck; F Krück
Journal:  Klin Wochenschr       Date:  1981-01-15

8.  Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man.

Authors:  R J MacFadyen; K R Lees; J D Gemmill; W S Hillis; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

9.  Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br Heart J       Date:  1991-09

10.  Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man.

Authors:  R J MacFadyen; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.